key: cord-0881320-l4zpoloa
authors: Aksoy, Nilay; Sancar, Mesut
title: QT prolongation risk with antiemetics during COVID 19 treatment
date: 2021-04-21
journal: Int J Clin Pract
DOI: 10.1111/ijcp.14041
sha: 750a5b099760e252ecd3d15d172c58dbd3c52575
doc_id: 881320
cord_uid: l4zpoloa

nan

Proposed treatments for COVID-19 initiate a concern in regard to the influential impact on cardiotoxicity and prolonged QT intervals.

Antiemetic agents pose an additional risk through the prolongations of QT intervals when medication is used concurrently with COVID-19 pharmacological therapies. 1 The fundamental understandings of the role of COVID-19 combination treatments in developing QT prolongation in hospitalised COVID-19 patients exhibiting nausea, vomiting, and gastrointestinal related complications remain unclear. Because adverse consequences are the attributes of a versatile range of causatives in the clinical nature of COVID-19, such as drugs, age, sex, or metabolic disorders (PH, hypoxia, electrolyte abnormalities, and multi-organ system failure), previous cardiovascular disease, and viral or autoimmune myocardial injuries. 2 Additionally, antiemetics may even be more important in the field of emergency surgical patients with COVID 19 who might be treated more likely with open surgery and therefore more prone to nausea and vomiting. [3] [4] [5] We searched the consequential risks of prolonging QT intervals on the virtual shelves of scientific databases by courtesy of To surpass the pandemic, healthcare providers of varying specialties from doctors to nurses, and well-rounded clinical pharmacists have to come together and merge expertise because sharing the adversities, will save more patients' life.

Institution-wide QT alert system identifies patients with a high risk of mortality

Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin

Adapting to an unprecedented scenario: surgery during the COVID-19 outbreak. Revista do Colégio Brasileiro de Cirurgiões

Convert to open: the new paradigm for surgery during COVID-19?

Laparoscopy at all costs? Not now during COVID-19 outbreak and not for acute care surgery and emergency colorectal surgery: a practical algorithm from a hub tertiary teaching hospital in Northern Lombardy

An algorithm for managing QT prolongation in Coronavirus Disease 2019 (COVID-19) patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin: Possible benefits of intravenous lidocaine

Hypokalemia and clinical implications in patients with coronavirus disease 2019 (COVID-19)

Considerations for drug interactions on QTc in exploratory COVID-19 (coronavirus disease 2019) treatment

FDA cautions against use of hydroxychloroquine or chloroquine for COVID-19 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems. U.S. Food and Drug Administration, FDA

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients